Author

Kasey Bolyard

Observed name: K. Bolyard

Institution: Johnson & Johnson (United States)

Observed institutions: Johnson & Johnson (United States), Janssen Research & Development (United States)

OpenAlex ID: A5113395932

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

2025 · Maria-Victoria Mateos, Jesus San-Miguel, et al. · The Lancet Oncology · 29

Unusual presentations of blastomycosis: ten case summaries.

1990 · Robert W. Bradsher, María Martín, et al. · 9

Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study.

2025 · Rakesh Popat, Alexa Laheij, et al. · Journal of Clinical Oncology · 4

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE

2026 · Nizar Bahlis, Thierry Facon, et al. · Blood Advances · 1

P47 | Utility and Sensitivity of Wett-sa53 to Measure Dysgeusia Associated With Talquetamab, a Gprc5d×cd3 Bispecific Antibody, in Relapsed/refractory Multiple Myeloma: Preliminary Data From the Talisman Study

2026 · R. Popat, N.W.C.J. Van De Donk, et al. · Haematologica · 1

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

2026 · Thierry Facon, Gordon Cook, et al. · Leukemia

PA-497 Timing and Resolution of Talquetamab-Related Dysgeusia in Relapsed/Refractory Multiple Myeloma (RRMM): Longitudinal Waterless Empirical Taste Test and Patient Reported Outcomes Profiles From TALisman

2026 · Ajai Chari, Niels WCJ van de Donk, et al. · Clinical Lymphoma Myeloma & Leukemia

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

2026 · Thierry Facon, Shaji K. Kumar, et al. · Leukemia

MM-793: Early Resolution of Talquetamab Oral Side Effects in Relapsed/Refractory Multiple Myeloma: Updated Waterless Empirical Taste Test and Patient-Reported Outcomes Data From TALisman

2026 · Niels WCJ van de Donk, Rakesh Popat, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: MM-793: Early Resolution of Talquetamab Oral Side Effects in Relapsed/Refractory Multiple Myeloma: Updated Waterless Empirical Taste Test and Patient-Reported Outcomes Data From TALisman

2026 · Niels Wcj van de Donk, Rakesh Popat, et al. · Clinical Lymphoma Myeloma & Leukemia

Age and frailty analyses of transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone (Rd) and bortezomib-Rd (VRd).

2026 · Christopher P. Venner, Sonja Zweegman, et al. · Journal of Clinical Oncology

Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study

2025 · Rakesh Popat, Niels W.C.J. van de Donk, et al. · Blood

P-324 Incidence, Timing, and Management of Infections in Patients Receiving Daratumumab for the Treatment of Newly Diagnosed Transplant-Ineligible Multiple Myeloma in the MAIA Study

2024 · Nizar J. Bahlis, Thierry Facon, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 13

Citation count: 44

H-index: 3

I10-index: 1